KalVista Pharmaceuticals
(NASDAQ) KALV
KalVista Pharmaceuticals Financials at a Glance
Market Cap
$993.20M
Revenue (TTM)
$75.04M
Net Income (TTM)
$167.18M
EPS (TTM)
$-4.00
P/E Ratio
-4.85
Dividend
$0.00
Beta (Volatility)
0.66 (Low)
Dividend
$0.00
Beta (Volatility)
0.66 (Low)
Price
$19.37
Volume
29,590
Open
$20.04
Price
$19.37
Volume
29,590
Open
$20.04
Previous Close
$19.37
Daily Range
$19.15 - $20.13
52-Week Range
$9.83 - $21.30
Dividend
$0.00
Beta (Volatility)
0.66 (Low)
Price
$19.37
Volume
29,590
Open
$20.04
Previous Close
$19.37
Daily Range
$19.15 - $20.13
52-Week Range
$9.83 - $21.30
KALV News
KALV: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout KalVista Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
275
CEO
Ben Palleiko, MBA
Website
www.kalvista.comHeadquarters
Cambridge, MA 02142, US
KALV Financials
Key Financial Metrics (TTM)
Gross Margin
69%
Operating Margin
-2%
Net Income Margin
-2%
Return on Equity
-190%
Return on Capital
-62%
Return on Assets
-50%
Earnings Yield
-20.62%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$993.20M
Shares Outstanding
51.22M
Volume
29.59K
Short Interest
0.00%
Avg. Volume
981.93K
Financials (TTM)
Gross Profit
$0.00
Operating Income
$188.00M
EBITDA
$173.33M
Operating Cash Flow
$152.91M
Capital Expenditure
$434.00K
Free Cash Flow
$153.34M
Cash & ST Invst.
$187.65M
Total Debt
$6.31M
KalVista Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$59.92M
N/A
Gross Profit
$54.15M
N/A
Gross Margin
90.36%
N/A
Market Cap
$993.20M
N/A
Market Cap/Employee
$6.62M
N/A
Employees
150
N/A
Net Income
$5.37M
+88.9%
EBITDA
$12.72M
+69.1%
Quarterly Fundamentals
Net Cash
$16.01M
-93.5%
Accounts Receivable
$11.30M
+20.2%
Inventory
$3.43M
N/A
Long Term Debt
$269.02M
+6101.4%
Short Term Debt
$15.19M
+951.9%
Return on Assets
-49.85%
N/A
Return on Invested Capital
-62.37%
N/A
Free Cash Flow
$45.52M
+238.7%
Operating Cash Flow
$45.36M
+238.8%